Late infections after blood progenitor cell transplantation in patients with multiple myeloma [1]

American Journal of Medicine

Volumn 110, Issue 4, 2001, Pages 329-330

  Steingrimsdottir, Hlif ^a   Gruber, Astrid ^a   Kalin, Mats ^a   Björkholm, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN;

ADULT; CLINICAL ARTICLE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LETTER; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE MYELOMA; PNEUMONIA; PRIORITY JOURNAL; STEM CELL; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMANS; INFECTION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PNEUMONIA, PNEUMOCOCCAL; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES; RISK; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 0035123260     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00725-7     Document Type: Letter

References (4)

1. A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
2. Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support
3. Infections following peripheral blood progenitor cell transplantation for lymphoprolipherative malignancies: Etiology and potential risk factors
4. Melphalan plus total body irradiation (MEL-total body irradiation) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone